menu
    • menu
    [{"orgOrder":0,"company":"CARGO Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Fludarabine Phosphate","moa":"DNA polymerase (alpha\/delta\/epsilon) | Ribonucleoside-diphosphate reductase RR1","graph1":"Oncology","graph2":"Phase II","graph3":"CARGO Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CARGO Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"CARGO Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"CARGO Therapeutics","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2023","type":"Public Offering","leadProduct":"CRG-022","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"CARGO Therapeutics","amount2":0.28000000000000003,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0.28000000000000003,"dosageForm":"Infusion","sponsorNew":"CARGO Therapeutics \/ J.P. Morgan","highestDevelopmentStatusID":"8","companyTruncated":"CARGO Therapeutics \/ J.P. Morgan"},{"orgOrder":0,"company":"CARGO Therapeutics","sponsor":"Third Rock Ventures","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2023","type":"Series A Financing","leadProduct":"CRG-022","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"CARGO Therapeutics","amount2":0.20000000000000001,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0.20000000000000001,"dosageForm":"Infusion","sponsorNew":"CARGO Therapeutics \/ Third Rock Ventures","highestDevelopmentStatusID":"8","companyTruncated":"CARGO Therapeutics \/ Third Rock Ventures"},{"orgOrder":0,"company":"CARGO Therapeutics","sponsor":"Concentra Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2025","type":"Acquisition","leadProduct":"CRG-023","moa":"CD19\/CD20\/CD22","graph1":"Oncology","graph2":"IND Enabling","graph3":"CARGO Therapeutics","amount2":0.22,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0.22,"dosageForm":"Undisclosed","sponsorNew":"CARGO Therapeutics \/ Concentra Biosciences","highestDevelopmentStatusID":"5","companyTruncated":"CARGO Therapeutics \/ Concentra Biosciences"}]

    Find Clinical Drug Pipeline Developments & Deals by CARGO Therapeutics

    Menu

    CARGO Therapeutics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            CARGO Therapeutics

                            U.S.A arrow
                            VMX
                            Not Confirmed

                            CARGO Therapeutics

                            U.S.A arrow
                            VMX
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CRG-023

                            Therapeutic Area : Oncology

                            Study Phase : IND Enabling

                            Sponsor : Concentra Biosciences

                            Deal Size : $217.5 million

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Concentra Acquires Cargo in $200M Buyout

                            Details : Through the acquisition of CRG-023, a cell and gene therapy targeting CD19/CD20/CD22, the deal aims to advance innovative treatment options in oncology.

                            Product Name : CRG-023

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Undisclosed

                            July 08, 2025

                            Lead Product(s) : CRG-023

                            Therapeutic Area : Oncology

                            Highest Development Status : IND Enabling

                            Sponsor : Concentra Biosciences

                            Deal Size : $217.5 million

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            CARGO Therapeutics

                            U.S.A arrow
                            VMX
                            Not Confirmed

                            CARGO Therapeutics

                            U.S.A arrow
                            VMX
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CRG-022

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : J.P. Morgan

                            Deal Size : $281.3 million

                            Deal Type : Public Offering

                            DEALS_DEV arrow-down

                            CARGO Therapeutics Announces Pricing of Initial Public Offering

                            Details : The net proceeds will be used to fund the development of CRG-022, an autologous CAR T-cell product candidate that targets CD22, currently in Phase I for Marginal Zone B-cell Lymphoma.

                            Product Name : Undisclosed

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Undisclosed

                            November 10, 2023

                            Lead Product(s) : CRG-022

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : J.P. Morgan

                            Deal Size : $281.3 million

                            Deal Type : Public Offering

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            CARGO Therapeutics

                            U.S.A arrow
                            VMX
                            Not Confirmed

                            CARGO Therapeutics

                            U.S.A arrow
                            VMX
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Fludarabine Phosphate,Cyclophosphamide,Firicabtagene Autoleucel

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Phase 2 Study of Firi-cel in Patients With Relapsed/Refractory Large B-cell Lymphoma

                            Details : Fludarabine is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            August 02, 2023

                            Lead Product(s) : Fludarabine Phosphate,Cyclophosphamide,Firicabtagene Autoleucel

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            CARGO Therapeutics

                            U.S.A arrow
                            VMX
                            Not Confirmed

                            CARGO Therapeutics

                            U.S.A arrow
                            VMX
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CRG-022

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Third Rock Ventures

                            Deal Size : $200.0 million

                            Deal Type : Series A Financing

                            DEALS_DEV arrow-down

                            CARGO Therapeutics Raises $200 Million in Oversubscribed, Upsized Series A Financing to Advance its Pipeline o...

                            Details : The proceeds from the financing will be used to advance CARGO’s autologous CD22 CAR T-cell therapy candidate, CRG-022, through a pivotal multicenter Phase 2 trial in patients with LBCL whose disease has relapsed or is refractory to CD19 CAR T-cell ther...

                            Product Name : Undisclosed

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Undisclosed

                            March 01, 2023

                            Lead Product(s) : CRG-022

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Third Rock Ventures

                            Deal Size : $200.0 million

                            Deal Type : Series A Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            • Privacy policy
                            • Terms and conditions
                            • Disclaimers
                            • LinkedIn
                            • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.